<SEC-DOCUMENT>0001193125-17-206012.txt : 20170616
<SEC-HEADER>0001193125-17-206012.hdr.sgml : 20170616
<ACCEPTANCE-DATETIME>20170616161727
ACCESSION NUMBER:		0001193125-17-206012
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20170616
DATE AS OF CHANGE:		20170616
EFFECTIVENESS DATE:		20170616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-218799
		FILM NUMBER:		17916350

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>d405567ds8.htm
<DESCRIPTION>S-8
<TEXT>
<HTML><HEAD>
<TITLE>S-8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on June&nbsp;16, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-8</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g405567g13e29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:ARIAL" ALIGN="center"><B>BIOGEN INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0112644</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>of incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>225 Binney Street, Cambridge, Massachusetts 02142 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>BIOGEN INC. 2017 OMNIBUS EQUITY PLAN </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Full
title of the plan) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUSAN H. ALEXANDER, ESQ. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Executive Vice President, Chief Legal, Corporate Services and Secretary </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Biogen Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>225 Binney Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, Massachusetts 02142 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">(617)&nbsp;679-2000</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a
smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title of Securities to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>to be</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Offering Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Per Share(2)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Offering Price(2)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Registration Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common Stock, $0.0005 par&nbsp;value per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">15,277,583 shares</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$254.13</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$3,882,492,167.79</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$449,980.84</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares to be registered is subject to adjustment by reason of stock splits, stock dividends and other events pursuant to the terms of the Biogen Inc. 2017 Omnibus Equity Plan (the &#147;2017
Plan&#148;). Accordingly, pursuant to Rule&nbsp;416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), this Registration Statement covers, in addition to the number of shares of common stock shown in the table above, an
indeterminate number of shares of the Registrant&#146;s common stock which may be subject to grant or otherwise issuable by operation of the provisions of the 2017 Plan governing such adjustments. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate
offering price are based upon the average of the high ($257.38) and low ($250.88) sales price for Registrant&#146;s common stock as reported on the NASDAQ Global Select Market on June&nbsp;14, 2017. </TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_1">PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_2">PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_3">Item&nbsp;3. Incorporation of Documents by Reference</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_4">Item&nbsp;4. Description of Securities</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_5">Item&nbsp;5. Interests of Named Experts and Counsel</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_6">Item&nbsp;6. Indemnification of Directors and Officers</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_7">Item&nbsp;7. Exemption From Registration Claimed</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_8">Item&nbsp;8. Exhibits</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_9">Item&nbsp;9. Undertakings</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_10">SIGNATURES AND POWER OF ATTORNEY</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx405567_11">EXHIBIT INDEX</A></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Ex-5</FONT> Opinion of Ropes&nbsp;&amp; Gray LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Ex-23.1</FONT> Consent of PricewaterhouseCoopers LLP</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9"><B><A NAME="tx405567_1"></A>PART I </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The documents containing the information required by Part I of this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> of Biogen Inc.
(&#147;Biogen&#148; or &#147;Registrant&#148;), Commission File Number <FONT STYLE="white-space:nowrap">000-19311,</FONT> will be sent or given to employees as specified by Rule 428 under the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;). In accordance with Rule 428 and the requirements of Part I of Form <FONT STYLE="white-space:nowrap">S-8,</FONT> such documents need not be filed with the Securities and Exchange Commission (the &#147;Commission&#148;) either as part of
this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this
Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
 COLOR="#0075c9"><B><A NAME="tx405567_2"></A>PART II </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_3"></A>Item&nbsp;3. Incorporation of Documents by Reference. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Biogen hereby incorporates the following documents filed with the Commission herein by reference: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Biogen&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016, filed on February&nbsp;2, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Biogen&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended March&nbsp;31, 2017, filed on April&nbsp;25, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Biogen&#146;s Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on January&nbsp;17, 2017, February&nbsp;1, 2017, February&nbsp;2, 2017, June&nbsp;9, 2017 and June 13, 2017 (except that any
portions thereof that are furnished and not filed shall not be deemed incorporated); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">The description of Biogen&#146;s common stock contained in the Registration Statement on Form <FONT STYLE="white-space:nowrap">8-B</FONT> filed on June&nbsp;2, 1997, including any amendment or report updating such
description of the common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">All documents subsequently filed by Biogen pursuant to Sections&nbsp;13(a), 13(c), 14 and 15(d) of the Securities
Exchange Act of 1934, as amended (&#147;Exchange Act&#148;), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to
be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be
deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any other subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_4"></A>Item&nbsp;4. Description of Securities. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_5"></A>Item&nbsp;5.
Interests of Named Experts and Counsel. </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_6"></A>Item&nbsp;6. Indemnification of Directors and Officers. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Article X of the Registrant&#146;s Amended and Restated Certificate of Incorporation, as amended, provides for the elimination of personal monetary liabilities of
directors of Biogen for any breach of their fiduciary duties to the full extent permitted by the General Corporation Law of Delaware (the &#147;GCL&#148;). Section&nbsp;102(b)(7) of the GCL enables a corporation in its certificate of incorporation
to eliminate or limit the personal liability of members of its board of directors to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided that the corporation shall not eliminate or limit the
liability of a director for: (i)&nbsp;breaching his or her duty of loyalty; (ii)&nbsp;failing to act in good faith, engaging in intentional misconduct or knowingly violating the law; (iii)&nbsp;paying an unlawful dividend or approving an illegal
stock repurchase; or (iv)&nbsp;obtaining an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the GCL provides that a corporation may indemnify directors and officers
as well as other employees and agents against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with specified actions, suits or proceedings, whether civil,
criminal, administrative or investigative (other than an action by or in the right of the corporation&nbsp;- a &#147;derivative action&#148;), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best
interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only
extends to expenses (including attorneys&#146; fees) actually and reasonably incurred in connection with the defense or settlement of such action, and the statute requires court approval before there can be any indemnification where the person
seeking indemnification has been found liable to the corporation. Indemnification provided pursuant to Section&nbsp;145 of the GCL is not exclusive of any other rights to which those seeking indemnification may be entitled to under any bylaw,
agreement, disinterested director vote, stockholder vote or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Registrant&#146;s Fourth Amended and Restated Bylaws provide that Biogen shall provide,
to the fullest extent authorized by the GCL, indemnification against all expense, liability and loss (including attorneys&#146; fees, judgments, fines, ERISA excise taxes or penalties, and amounts paid or to be paid in settlement) reasonably
incurred by its directors, officers, or any other person who is or was serving at the request of Biogen as a director, officer, employee or agent of another related entity and shall advance expenses to such persons, in respect of any action, suit or
proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was serving in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition, Biogen
maintains directors&#146; and officers&#146; liability insurance which insures against certain liabilities that directors or officers of Biogen may incur in such capacities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Biogen also has in place agreements with certain of its officers and directors which affirm Biogen&#146;s obligation to indemnify them to the fullest extent permitted
by law and contain various procedural and other provisions which expand the protection afforded by Biogen&#146;s Bylaws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_7">
</A>Item&nbsp;7. Exemption From Registration Claimed. </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_8"></A>Item&nbsp;8. Exhibits. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The exhibits listed on the Exhibit&nbsp;Index immediately preceding such exhibits are filed as part of this Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#0075c9"><B><A NAME="tx405567_9"></A>Item&nbsp;9. Undertakings. </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The undersigned Registrant hereby undertakes: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">To include any prospectus required by Section 10(a)(3) of the Securities Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering
price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>provided, however</I>, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall not apply if the information required to be included in
a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section&nbsp;13 or Section 15(d) of the Exchange Act that are incorporated by reference in the
Registration Statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#146;s annual report pursuant to Section 13(a) or Section 15(d) of the
Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration
Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the
Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9"><B><A NAME="tx405567_10"></A>SIGNATURES AND POWER OF ATTORNEY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">S-8</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of
Massachusetts, on June&nbsp;16, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOGEN INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Michel Vounatsos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michel Vounatsos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the
following persons in the capacities indicated on June&nbsp;16, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, we, the undersigned officers and directors of the Registrant hereby
severally constitute and appoint Michel Vounatsos, Paul J. Clancy and Susan H. Alexander and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities as
indicated, any and all amendments or supplements to this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> of the Registrant, including post-effective amendments to the Registration Statement, and generally to do all such
things in connection therewith in our name and on our behalf in our capacities as indicated to enable the Registrant to comply with the provisions of the Securities Act of 1933 and all requirements of the Securities and Exchange Commission, hereby
ratifying and confirming our signatures as they may be signed by our said attorneys or any of them, to any and all amendments. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:21.35pt; font-size:8pt; font-family:ARIAL">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:31.15pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Capacity</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Michel Vounatsos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Michel Vounatsos</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Director and Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(Principal Executive
Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Paul J. Clancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Paul J. Clancy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Executive Vice President and Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(Principal
Financial Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Gregory F. Covino</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Gregory F. Covino</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vice President and Chief Accounting Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(Principal
Accounting Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Stelios Papadopoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Stelios Papadopoulos</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Chairman of the Board of Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Alexander J. Denner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Alexander J. Denner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Caroline D. Dorsa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Caroline D. Dorsa</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Nancy L. Leaming</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Nancy L. Leaming</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Richard C. Mulligan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Richard C. Mulligan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:21.35pt; font-size:8pt; font-family:ARIAL">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:31.15pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Capacity</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Robert W. Pangia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Robert W. Pangia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Brian S. Posner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Brian S. Posner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Eric K. Rowinsky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Eric K. Rowinsky</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Lynn Schenk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Lynn Schenk</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Stephen A. Sherwin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">Stephen A. Sherwin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0075c9"><B><A NAME="tx405567_11"></A>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.15pt; font-size:8pt; font-family:ARIAL">Exhibit*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:40.05pt; font-size:8pt; font-family:ARIAL">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
June&nbsp;30, 2012.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;27,
2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on June&nbsp;9, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5 +</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Ropes&nbsp;&amp; Gray LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1&nbsp;+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2 +</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ropes&nbsp;&amp; Gray LLP (included in its opinion in Exhibit&nbsp;5).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24 +</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Powers of Attorney (contained in Part II hereof under Signatures and Power of Attorney).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>99</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix&nbsp;B to Biogen&#146;s Definitive Proxy Statement on Schedule&nbsp;14A filed on April&nbsp;26, 2017.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Unless otherwise indicated, exhibits were previously filed with the Securities and Exchange Commission under Commission File Number <FONT STYLE="white-space:nowrap">000-19311</FONT> and are incorporated herein by
reference. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5
<SEQUENCE>2
<FILENAME>d405567dex5.htm
<DESCRIPTION>EX-5
<TEXT>
<HTML><HEAD>
<TITLE>EX-5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 5 </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">


<IMG SRC="g405567g60d92.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">ROPES &amp; GRAY LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">PRUDENTIAL TOWER</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">800 BOYLSTON STREET</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">BOSTON, MA 02199-3600</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">WWW.ROPESGRAY.COM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;16, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biogen Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">225 Binney Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter is furnished to you in connection with a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (the &#147;<U>Registration
Statement</U>&#148;), filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), for the registration of 15,277,583 shares of common stock, $0.0005 par value per share (the
&#147;<U>Shares</U>&#148;), of Biogen Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;). The Shares are issuable under the Company&#146;s 2017 Omnibus Equity Plan (the &#147;<U>Plan</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are familiar with the actions taken by the Company in connection with the adoption of the Plan. We have examined such certificates, documents and records,
and have made such investigation of fact and such examination of law, as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification,
upon certificates of officers of the Company, public officials and other appropriate persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed below are limited to the Delaware
General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized, and, when the Shares
have been issued and sold in accordance with the terms of the Plan, the Shares will be validly issued, fully paid and nonassessable. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this letter as an exhibit to the Registration Statement. Our consent shall not
be deemed an admission that we are experts whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ropes&nbsp;&amp; Gray LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d405567dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 23.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> of our report<SUP
STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;dated February&nbsp;2, 2017 relating to the financial statements, and the effectiveness of internal control over financial reporting, which appears in Biogen Inc.&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 16, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g405567g13e29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g405567g13e29.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MNKQG0;E0!%'W78GC^=O%/C&GQ-@\/DV3TG_9^&Q"Q%6M67)5KU(1G"'LH/\
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MKA:E@<=_:N.Q]?.,T4>2-:O:,:4;6?LJ<;J+LVM92LF[)-MOZ1KY$^J"@ H
M* *-YJ>FZ;Y7]H:A8V'G;_)^V7=O:^;Y>SS/*\^1=^W>F=N<;USU%<6,S++L
MN]G]?S##8#VW-[/ZQ7I4.?DY>;D]I*/-R\T>;EOR\T;VNCJPV!QN-Y_J>#KX
MOV5N?V-*I5Y.:_+S<D9<O-RRM>U[.VS+U=IRA0 4 % !0 4 % !0 4 % !0
M4 % !0 4 >'_ !E_YEO_ +C'_N+K\5\8/^:=_P"Y_P#]TC]0\-_^9S_W*?\
$NT?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g405567g60d92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g405567g60d92.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M!Q]WS=0U;Q5XQO5!_O\ D7^E$^S)ZU+TA%>;?Y(M+][)_P L8K\6SZ#J#4*
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MA/Y?F:3TJ4?)R_(M_LIK)>:%\6?$TT<J3>*?CI\1=14RQLC/:V=W9Z3:,N\
MM%Y=@=IZ<G%*>G*OY4@HJRF]KSE_D9'[.<,ND>-_VI_#+QR10V7Q=N]=LU='
M1&@\4Z1'J&Z$LH#KOB()7(SQ3EM#TM]PJ7NRK1[2O]Z+'[$44L/[/?AR.6*2
M%UUWQ@2DL;Q. ?$NHE24=00",$<4JGQ>B7Y#P^E)=+-_F?6U0;!0 4 % !0
>4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
